These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22477764)

  • 1. Successful sealing of a coronary artery perforation with a mesh-covered stent.
    Fogarassy G; Apró D; Veress G
    J Invasive Cardiol; 2012 Apr; 24(4):E80-3. PubMed ID: 22477764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel use of the Mguard mesh-covered stent to treat coronary arterial perforations.
    Romaguera R; Gomez-Hospital JA; Cequier A
    Catheter Cardiovasc Interv; 2012 Jul; 80(1):75-8. PubMed ID: 22511569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of coronary artery perforations complicating percutaneous coronary intervention with a polytetrafluoroethylene-covered stent graft.
    Lansky AJ; Yang YM; Khan Y; Costa RA; Pietras C; Tsuchiya Y; Cristea E; Collins M; Mehran R; Dangas GD; Moses JW; Leon MB; Stone GW
    Am J Cardiol; 2006 Aug; 98(3):370-4. PubMed ID: 16860026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial.
    Liistro F; Porto I; Angioli P; Grotti S; Ducci K; Falsini G; Bolognese L
    Am Heart J; 2013 Nov; 166(5):920-6. PubMed ID: 24176449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optical coherence tomography (OCT) in PCI for in-stent restenosis (ISR): rationale and design of the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) study.
    Adriaenssens T; Dens J; Ughi G; Coosemans M; Onsea K; Dubois C; Sinnaeve P; Vrolix M; Desmet W
    EuroIntervention; 2011 May; 7 Suppl K():K100-5. PubMed ID: 22027717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bailout polytetrafluoroethylene-covered stent implantation for left main bifurcation perforation using the kissing stent technique.
    Moriyama N; Tanaka Y; Saito S
    Catheter Cardiovasc Interv; 2017 May; 89(6):1022-1027. PubMed ID: 28145616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.
    Ota H; Mahmoudi M; Kitabata H; Torguson R; Chen F; Satler LF; Suddath WO; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2015 Mar; 16(2):84-9. PubMed ID: 25870152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial.
    Moreno R; Garcia E; Teles RC; Almeida MS; Carvalho HC; Sabate M; Martin-Reyes R; Rumoroso JR; Galeote G; Goicolea FJ; Moreu J; Mainar V; Mauri J; Ferreira R; Valdes M; Perez de Prado A; Martin-Yuste V; Jimenez-Valero S; Sanchez-Recalde A; Calvo L; Lopez de Sa E; Macaya C; Lopez-Sendon JL
    EuroIntervention; 2010 May; 6(1):112-6. PubMed ID: 20542806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
    Hofma SH; Brouwer J; Velders MA; van't Hof AW; Smits PC; Queré M; de Vries CJ; van Boven AJ
    J Am Coll Cardiol; 2012 Jul; 60(5):381-7. PubMed ID: 22835668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iatrogenic acute coronary dissection during coronary angioplasty for in-stent restenosis: role of intravascular ultrasound in diagnosis and treatment.
    Park CB; Park HK; Kim CJ
    J Invasive Cardiol; 2012 Jan; 24(1):E1-2. PubMed ID: 22210589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PK Papyrus covered stent: Device description and early experience for the treatment of coronary artery perforations.
    Kandzari DE; Birkemeyer R
    Catheter Cardiovasc Interv; 2019 Oct; 94(4):564-568. PubMed ID: 31033148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment and outcome of coronary artery perforations using a dual guiding catheter technique.
    Röther J; Tröbs M; Ludwig J; Achenbach S; Schlundt C
    Int J Cardiol; 2015 Dec; 201():479-83. PubMed ID: 26313871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
    Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
    Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary perforation in the drug-eluting stent era: incidence, risk factors, management and outcome: the UK experience.
    Hendry C; Fraser D; Eichhofer J; Mamas MA; Fath-Ordoubadi F; El-Omar M; Williams P
    EuroIntervention; 2012 May; 8(1):79-86. PubMed ID: 22580251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
    Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
    Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IVUS-guided management of late stent malaposition with peri-stent restenosis with coronary artery aneurysm following drug-eluting stent implantation (paxlitaxel-eluting stent).
    Lanjewar CP; Sharma A; Sheth T
    J Invasive Cardiol; 2009 May; 21(5):E87-90. PubMed ID: 19411733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fracture of a paclitaxol-eluting stent implanted for in-stent restenosis at the site of sirolimus-eluting stent fracture.
    Watanabe T; Tamura A; Miyamoto K; Kadota J
    Int J Cardiol; 2010 Apr; 140(1):e12-3. PubMed ID: 19059662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed comparison of intra-stent conditions 12 months after implantation of everolimus-eluting stents in patients with ST-segment elevation myocardial infarction or stable angina pectoris.
    Mizoguchi T; Sawada T; Shinke T; Yamada S; Okamoto H; Kim SS; Takarada A; Yasaka Y
    Int J Cardiol; 2014 Feb; 171(2):224-30. PubMed ID: 24388538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.